Venthera

Venthera is a small biotechnology company based in Palo Alto, California, with fewer than five employees. The company focuses on developing innovative treatments for patients suffering from specific types of birthmarks. Venthera's primary focus is on developing a topical PI3K inhibitor to treat cutaneous venous malformations (VMs) and lymphatic malformations (LMs). These malformations, often present from birth, can cause a range of complications, including pain, bleeding, and disfigurement. The company's therapeutic approach targets the underlying genetic mutations that drive many VMs and LMs, specifically mutations in PI3K or its upstream driver, TIE2. By inhibiting PI3K, Venthera aims to safely and effectively treat these lesions at their source. For more information about Venthera and its innovative treatments, visit their website at ventera.com.